Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Delta Air Lines, Inc. (NYSE: DAL) shares spiked 5.71 percent to close at $34.45 a share Tuesday. The stock traded between $33.49 and $34.72 on volume 13.58 million shares traded. The company reported consolidated passenger unit revenue increased 4.0 percent year-over-year in February. Shares of Delta Air Lines are up approximately 25.0 percent year-to-date.
Get more information on Delta Air Lines free access to the in-depth equity report at:
Guidewire Software Inc. (NYSE: GWRE) shares gained 7.94 percent to close at $57.38 a share Monday. The stock traded between $55.53 and $58.00 on volume of 1.80 million shares traded. The company reported revenue totaled $83.5 million for the second quarter of fiscal 2014, an increase of 16.0 percent when compared to a year ago. Shares of Guidewire Software are up approximately 16.0 percent year-to-date.
Get more information on Guidewire Software and free access to the in-depth equity report at:
MBIA Inc. (NYSE: MBI) shares surged 11.41 percent to close at $14.73 a share Tuesday. The stock traded between $13.75 and $14.87 on volume 12.14 million shares traded. The company reported earnings of $0.68 a share for the fourth quarter of 2013, which topped analysts’ expectations of $0.62 a share. Shares of MBIA are up approximately 24.0 percent year-to-date.
Get more information on MBIA and free access to the in-depth equity report at:
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) shares declined 4.88 percent to close at $6.45 a share Monday. The stock traded between $5.72 and $6.60 on volume of 9.33 million shares traded. The company announced that Safi R. Bahcall, Ph.D., has resigned as President, Chief Executive Officer, effective immediately. Shares of Synta Pharmaceuticals are up approximately 23.0 percent year-to-date.
Get more information on Synta Pharmaceuticals and free access to the in-depth equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Five Star Equities